Search

Diabetic cognitive dysfunction has gained widespread attention for its deleterious impact on individuals with diabetes. However, few clinical interventions are available to prevent the disorder. The glucagon-like peptide-1 analog liraglutide exerts neuroprotective effects in several models of neurodegenerative diseases. We investigated the effect of liraglutide pretreatment on diabetes-induced cognitive decline and explored the underlying mechanisms in vivo and in vitro . Liraglutide pretreatment prevented diabetes-induced cognitive impairment as assessed by the Morris Water Maze test, and alleviated neuronal injuries and ultrastructural damage to synapses in the hippocampal CA1 region. Furthermore, liraglutide promoted autophagy as indicated by enhanced expression of the autophagy markers Microtubule-associated protein 1 light chain 3 (LC3)-II and Beclin 1, decreased expression of p62, and increased formation of autophagic vacuoles and LC3-II aggregates. In vitro , liraglutide treatment elevated phosphorylated (p)-AMP-activated protein kinase (AMPK) levels and reduced p-mammalian target of rapamycin (p-mTOR) expression. Additionally, the AMPK inhibitor Compound C exhibited an inhibitory effect on liraglutide-induced increased LC3-II expression and p62 degradation. Liraglutide exhibits neuroprotective effects against diabetes-induced hippocampal neuronal injuries and cognitive impairment by promoting autophagy via the AMPK/mTOR pathway. [ABSTRACT FROM AUTHOR]

• Correlation of Vitek 2 and agar dilution for levofloxacin AST with 2019 CLSI breakpoints. • Category agreement declined for Vitek 2 based on revised criteria in Enterobacterales. • MICs measured by both testing methods were associated with clinical outcomes. • Laboratory and clinical evidence of Vitek 2 performance to verify updated breakpoints. In 2019, the CLSI lowered the susceptible levofloxacin breakpoints for Enterobacterales from a MIC of ≤2 μg/mL to ≤0.5 μg/mL. The study evaluated the correlation between the susceptibility profiles obtained by the Vitek 2 and agar dilution (AD) methods in levofloxacin MIC ≤2 μg/mL isolates and its clinical impacts. Two hundred fifty-three Enterobacterales isolates and 222 patients treated with levofloxacin for Enterobacterales bacteremia were enrolled for analysis. There was 86.2% categorical agreement, 5 very major errors, and 30 minor errors based on the 2019 CLSI breakpoints. Higher levofloxacin MICs (1 or 2 μg/mL) determined using Vitek 2 or AD predicted early clinical failure (P < 0.001 for Vitek 2 and P = 0.001 for AD). In conclusion, Vitek 2 performance for levofloxacin susceptibility testing of Enterobacterales declined according to the 2019 CLSI criteria compared with the pre-2019 criteria. Although discrepant results were obtained, the MICs measured by Vitek 2 could still predict treatment outcomes. [ABSTRACT FROM AUTHOR]

Abstract: This research proposes a newly developed stray light filter in order to eliminate stray light, which otherwise might severely reduce the performance of the con-focal microscopy presented in this research. First, an optical design for con-focal microscopy with a digital micro-mirror device (DMD) is illustrated; second, a newly developed stray light filter is presented, which functions to eliminate possible stray light and ghost images without any sacrifice of luminance. It indicates that not only can the optical system be much simplified but also that its resolution could be one step higher, because the system employs neither a pinhole nor a CCD camera lens. Experimental results are shown in the paper, demonstrating an increase in contrast of up to 60%. [ABSTRACT FROM AUTHOR]